Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR plus MBC)

被引：0
|
作者：
Blakely, L. J.
Schwartzberg, L. S.
Wang, G.
Somer, B. G.
Wheeler, B. M.
Stepanski, E. J.
Walker, M.
Johns, A.
机构：
[1] West Clin, Memphis, TN USA
[2] Adv Med Specialties, Miami, FL USA
[3] ACORN Res, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e11087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e11087
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
    Barroso-Sousa, Romualdo
    Krop, Ian E.
    Trippa, Lorenzo
    Tan-Wasielewski, Zhenying
    Li, Tianyu
    Osmani, Wafa
    Andrews, Chelsea
    Dillon, Deborah
    Richardson, Edward T., III
    Pastorello, Ricardo G.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Bellon, Jennifer R.
    Schoenfeld, Jonathan D.
    Tolaney, Sara M.
    CLINICAL BREAST CANCER, 2020, 20 (03) : 238 - 245
  • [32] Phase II trial of paclitaxel polyglumex (PPX) with capecitabine (C) for metastatic breast cancer (MBC)
    Northfelt, D. W.
    Allred, J. B.
    Liu, H.
    Hobday, T. J.
    Rodacker, M. W.
    Lyss, A. P.
    Fitch, T. R.
    Perez, E. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] A phase I trial to evaluate the safety of the addition of alisertib to fulvestrant in hormone receptor positive (HR plus ), advanced breast cancer
    Haddad, T. C.
    D'Assoro, A. B.
    Suman, V. J.
    Opyrchal, M.
    Goetz, M. P.
    Ingle, J. N.
    CANCER RESEARCH, 2016, 76
  • [34] Saci-IO HR plus : Randomized phase II trial of sacituzumab govitecan (SG) plus /- pembrolizumab in PD-L1+hormone receptor-positive (HR+) / HER2-metastatic breast cancer (MBC).
    Garrido-Castro, Ana Christina
    Keenan, Tanya Elizabeth
    Li, Tianyu
    Lange, Paulina
    Callahan, Catherine
    Guerriero, Jennifer
    Tayob, Nabihah
    Anderson, Leilani
    Stover, Daniel G.
    Gogineni, Keerthi
    Carey, Lisa A.
    Nanda, Rita
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Tolaney, Sara M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [35] Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
    Sarah Sammons
    Noah S. Kornblum
    Kimberly L. Blackwell
    Targeted Oncology, 2019, 14 : 1 - 12
  • [36] Outcomes with CDK4/6 inhibitors based on endocrine sensitivity in hormone receptor-positive metastatic breast cancer (HR plus MBC).
    Jain, Amit L.
    Mullins, Janice Nhan
    Poorman, Kelsey Anne
    Chaudhry, Amina
    Ranganath, Harsha Avinash
    Miller, Emily McCollum
    Valasareddy, Poojitha
    Smith, Justin R.
    Ryder, Julie
    Winerip, Michelle
    Schwartzberg, Lee S.
    Vidal, Gregory A.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [37] Fulvestrant-Based Combination Therapy for Second-Line Treatment of Hormone Receptor-Positive Advanced Breast Cancer
    Sammons, Sarah
    Kornblum, Noah S.
    Blackwell, Kimberly L.
    TARGETED ONCOLOGY, 2019, 14 (01) : 1 - 12
  • [38] Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR plus ) metastatic breast cancer (MBC)
    Shah, Payal D.
    Moynahan, Mary Ellen
    Modi, Shanu
    Caravella, Betty Ann
    Datko, Farrah M.
    Zamora, Stephen
    Comen, Elizabeth
    Gilewski, Theresa
    Sugarman, Steven M.
    D'Andrea, Gabriella
    Lake, Diana E.
    Goldfarb, Shari B.
    Patil, Sujata
    Covey, Anne
    Berger, Michael F.
    Lacouture, Mario E.
    Norton, Larry
    Hudis, Clifford A.
    Baselga, Jose
    Chandarlapaty, Sarat
    Dickler, Maura N.
    CANCER RESEARCH, 2015, 75
  • [39] Randomized phase II study of fulvestrant with or without ganetespib in patients (pts) with hormone receptor (HR)-positive metastatic breast cancer
    Lin, N. U.
    Whitesell, L.
    Gelman, R.
    Mayer, E.
    Krop, I. E.
    Santagata, S.
    Lowe, A.
    Proia, D.
    Farooq, S.
    Brown, M.
    Lannone, M.
    Lindquist, S.
    Winer, E. P.
    CANCER RESEARCH, 2013, 73
  • [40] Metronomic vinorelbine, cyclophosphamide plus capecitabine (VEX) combination: a phase II study for metastatic breast cancer patients
    Montagna, E.
    Palazzo, A.
    Cancello, G.
    Iorfida, M.
    Sciandivasci, A.
    Cardillo, A.
    Mazza, M.
    Munzone, E.
    Campenni, G. M.
    Bianco, N.
    Sortino, G.
    Rinaldi, L.
    Esposito, A.
    Colleoni, M.
    ANNALS OF ONCOLOGY, 2016, 27
12345